论文部分内容阅读
目的研究Tulasi对接受~(137)Cs-γ射线全身照射小鼠的防护作用。方法将Swiss小鼠分为对照组和处理组,采用~(137)Cs-γ射线对两组小鼠进行不同剂量单次全身照射;其中处理组小鼠在照射前1 d给予Tulasi(20 mg/kg),采用最大耐受量评价Tulasi的用药安全性,观察小鼠30 d存活率、肝脏丙二醛(MDA)和还原型谷胱甘肽(GSH)的含量。结果 Tulasi具有很好的用药安全性,最大耐受量为275 mg/kg,能显著提高辐射小鼠的30 d生存率,处理组与对照相比,差异有高度统计学意义(P<0.001);对照组肝脏MDA的含量明显较处理组高,而GSH的含量则明显低于处理组,两者差异均有高度统计学意义(P<0.001)。结论 Tulasi对接受全身照射的小鼠具有明显的辐射防护作用。
Objective To study the protective effect of Tulasi on mice receiving systemic exposure to 137 Cs-γ-ray. Methods Swiss mice were divided into control group and treatment group. All the mice were irradiated with ~ (137) Cs-γ ray at different doses for one whole body irradiation. The mice in the treatment group were given Tulasi (20 mg / kg). The maximum tolerability was used to evaluate the safety of Tulasi. The 30-day survival rate, liver malondialdehyde (MDA) and reduced glutathione (GSH) were observed. Results Tulasi had good drug safety with the maximum tolerated dose of 275 mg / kg, which significantly increased the 30-day survival rate of irradiated mice. The difference between the two groups was statistically significant (P <0.001) ; The content of MDA in the liver of the control group was significantly higher than that of the treated group, while the content of GSH was significantly lower than that of the untreated group. The differences between the two groups were highly statistically significant (P <0.001). Conclusion Tulasi has a significant radioprotective effect on mice receiving whole body irradiation.